{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:48:34Z","timestamp":1793296114864,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010983","name":"Health Research Fund of Central Denmark Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","geriatriconcology.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jgo.2020.12.008","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T01:49:02Z","timestamp":1609379342000},"page":"827-833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity"],"prefix":"10.1016","volume":"12","author":[{"given":"Carina K.","family":"Hermansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jgo.2020.12.008_bb0005","first-page":"507","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jgo.2020.12.008_bb0010","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.critrevonc.2008.08.002","article-title":"The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG taskforce","volume":"69","author":"Bellmunt","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"10.1016\/j.jgo.2020.12.008_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30125-6","article-title":"Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology","volume":"19","author":"Kanesvaran","year":"2018","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.jgo.2020.12.008_bb0020","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jgo.2020.12.008_bb0025","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgo.2020.12.008_bb0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2147\/CLEP.S258755","article-title":"Registrations of patients with renal cell carcinoma in the Nationwide Danish renal Cancer database versus the Danish Cancer registry: data quality, completeness and survival (DaRenCa Study-3)","volume":"12","author":"Danckert","year":"2020","journal-title":"Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jgo.2020.12.008_bb0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ejca.2013.10.010","article-title":"Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish renal Cancer group (DARENCA) study-2","volume":"50","author":"Soerensen","year":"2014","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.jgo.2020.12.008_bb0040","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2165\/11592880-000000000-00000","article-title":"Systemic therapies for metastatic renal cell carcinoma in older adults","volume":"28","author":"Pal","year":"2011","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.jgo.2020.12.008_bb0045","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.cger.2013.07.002","article-title":"Normal cognitive aging","volume":"29","author":"Harada","year":"2013","journal-title":"Clin Geriatr Med"},{"issue":"4","key":"10.1016\/j.jgo.2020.12.008_bb0050","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.amjopharm.2004.12.005","article-title":"Pharmacokinetics in older persons","volume":"2","author":"Cusack","year":"2004","journal-title":"Am J Geriatr Pharmacother"},{"issue":"1","key":"10.1016\/j.jgo.2020.12.008_bb0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"34","key":"10.1016\/j.jgo.2020.12.008_bb0060","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2020.12.008_bb0065","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jgo.2012.11.001","article-title":"Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma","volume":"4","author":"Pal","year":"2013","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.jgo.2020.12.008_bb0070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ctrv.2016.02.006","article-title":"Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis","volume":"45","author":"Nishijima","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.jgo.2020.12.008_bb0075","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1093\/annonc\/mdy228","article-title":"Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide","volume":"29","author":"Scott\u00e9","year":"2018","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1016\/j.jgo.2020.12.008_bb0080","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1002\/cncr.28151","article-title":"Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the international mRCC database consortium criteria","volume":"119","author":"Kroeger","year":"2013","journal-title":"Cancer."},{"issue":"20","key":"10.1016\/j.jgo.2020.12.008_bb0085","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/jnci\/djn319","article-title":"Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial","volume":"100","author":"Eisen","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.jgo.2020.12.008_bb0090","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.eururo.2011.12.057","article-title":"Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 trial","volume":"61","author":"Porta","year":"2012","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.jgo.2020.12.008_bb0095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bjc.2012.543","article-title":"Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis","volume":"108","author":"Procopio","year":"2013","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2020.12.008_bb0100","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.eururo.2017.02.010","article-title":"CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for Nivolumab versus Everolimus in advanced renal cell carcinoma","volume":"72","author":"Escudier","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jgo.2020.12.008_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2019.10.032","article-title":"Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma","volume":"126","author":"Donskov","year":"2020","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2020.12.008_bb0110","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clgc.2014.02.009","article-title":"Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population","volume":"12","author":"Khambati","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2020.12.008_bb0115","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/bjc.2013.832","article-title":"Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma","volume":"110","author":"Hutson","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jgo.2020.12.008_bb0120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clgc.2013.11.005","article-title":"Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis","volume":"12","author":"De Giorgi","year":"2014","journal-title":"Clin Genitourin Cancer"},{"issue":"4\u20135","key":"10.1016\/j.jgo.2020.12.008_bb0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.euf.2017.11.008","article-title":"Immunotherapy in the elderly","volume":"3","author":"Lalani","year":"2017","journal-title":"Eur Urol Focus"},{"issue":"3","key":"10.1016\/j.jgo.2020.12.008_bb0130","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/cncr.29773","volume":"122","author":"Kaymakcalan","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jgo.2020.12.008_bb0135","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.21873\/anticanres.12633","article-title":"Significance of age in Japanese patients receiving Sunitinib as first-line systemic therapy for metastatic renal cell carcinoma: comparative assessment of efficacy and safety between patients aged <75 and >\/=75 years","volume":"38","author":"Miyake","year":"2018","journal-title":"Anticancer Res"},{"issue":"13","key":"10.1016\/j.jgo.2020.12.008_bb0140","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","article-title":"Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma","volume":"24","author":"Sternberg","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.jgo.2020.12.008_bb0145","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-18-0291","article-title":"Goldilocks dosing of TKIs: a dose that is just right leads to optimal outcomes","volume":"24","author":"Rini","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jgo.2020.12.008_bb0150","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/bju.12940","article-title":"Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma","volume":"117","author":"Rautiola","year":"2016","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.jgo.2020.12.008_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000891","article-title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","volume":"8","author":"Motzer","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jgo.2020.12.008_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020565","article-title":"New first line treatment options of clear cell renal cell Cancer patients with PD-1 or PD-L1 immune-checkpoint inhibitor-based combination therapies","volume":"9","author":"Grimm","year":"2020","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.jgo.2020.12.008_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30348-6","article-title":"Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer","volume":"19","author":"Soto-Perez-de-Celis","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2020.12.008_bb0170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.critrevonc.2005.06.003","article-title":"Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG)","volume":"55","author":"Extermann","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.jgo.2020.12.008_bb0175","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2002.20.2.494","article-title":"Comprehensive geriatric assessment adds information to eastern cooperative oncology group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study","volume":"20","author":"Repetto","year":"2002","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.jgo.2020.12.008_bb0180","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1200\/JCO.2017.72.8170","article-title":"Time to stop saying geriatric assessment is too time consuming","volume":"35","author":"Hamaker","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2020.12.008_bb0185","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2017.06.027","article-title":"Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer","volume":"83","author":"Martinez-Tapia","year":"2017","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.jgo.2020.12.008_bb0190","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820305300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406820305300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T09:52:58Z","timestamp":1761817978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406820305300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S1879406820305300"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2020.12.008","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2020.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}